Clinical requirements for medicines intended for the treatment of sickle cell disease
HumanScientific guidelines
Maltese is available via eTranslation, the European Commission's machine translation service.
Translate to Maltese | Important information about machine translation
This guideline aims at providing guidance on general principles of the clinical development programme of medicinal products for the treatment of sickle cell disease (SCD). This guideline focuses on the confirmatory phase 3 trials investigating safety and efficacy and serving as the main basis for benefit risk assessment of these products.
Keywords: Sickle Cell Disease (SCD), vaso-occlusive crises (VOC), haemolysis, haemolytic anaemia, transfusion